|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Because activation of the innate cellular immune response, mediated by microglia, has been linked to the neurodegeneration in PD, in the present study, we evaluated the effects of lipopolysaccharide (LPS) and 6-hydroxydopamine (6-OHDA) on microglia's morphology, reflective of their activity, as well as tyrosine hydroxylase (TH)-positive neurons in SNpc and motor behavior.
|
31478124 |
2020 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Following the establishment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD) model, AQP4-deficient (AQP4<sup>-/-</sup> ) mice displayed significantly stronger microglial inflammatory responses and remarkably greater losses of tyrosine hydroxylase (TH<sup>+</sup> )-positive neurons than did wild-type AQP4 (AQP4<sup>+/+</sup> ) controls.
|
30680924 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, immunohistochemistry for tyrosine hydroxylase (TH) revealed a significant reduction in the number of DAergic neurons in the substantia nigra of PD mice following BCCAS, particularly in the PDMCI + BCCAS group.
|
30959125 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Tyrosine hydroxylase (TH) was increased significantly and <i>α</i>-synuclein protein expression was reduced in the EX-PD group compared to the SED-PD group.
|
31309116 |
2019 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Meta-analysis results revealed statistically significant effects of acupuncture for increasing both TH levels (33.97 [95% CI 33.15-34.79]; <i>p</i> < 0.00001) and dopamine content (4.23 [95% CI 3.53-4.92]; <i>p</i> < 0.00001) compared with that observed in PD control groups.
|
31139074 |
2019 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We further assessed AUR effects in vivo, investigating tyrosine hydroxylase (TH) expression in the striatum and substantia nigra of MPTP-induced PD model mice and behavioral changes after injection of AUR.
|
31336718 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of PD, 17e significantly attenuated loss of tyrosine hydroxylase-immunopositive dopaminergic neurons, suppressed microglial activation, and alleviated PD-associated motor dysfunction.
|
30540174 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Finally, upregulation of miR-190 inhibited the activation of microglial cells and inflammation and attenuated the tyrosine hydroxylase loss in SNpc in MPTP-induced PD mice.
|
31232472 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings provide important insights into the topography of nigrostriatal neurodegeneration in Parkinson's disease, indicating that the characteristics of disease progression may fundamentally differ across hemispheres and support post-mortem data showing asynchrony in the loss of neuromelanin-containing versus tyrosine hydroxylase positive nigral cells.
|
31056699 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
ECH reversed the reduction of total distance in open field test in MPTP-induced PD model mice (P < 0.01), shortened the return time and total time of PD subacute model mice in pole test (P < 0.01, P < 0.05), significantly reversed the reduction of TH positive neurons induced by MPTP (P < 0.05), and reduced the activation of astrocytes (P < 0.05).
|
30834264 |
2019 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Thirty-one patients with impulsive compulsive behaviours and Parkinson's disease who donated their brains to the Queen Square Brain Bank for Neurological Disorders were assessed for α-synuclein neuropathological load and tyrosine hydroxylase levels in the nucleus accumbens, dorsal putamen and caudate using immunohistochemistry.
|
31603207 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Altogether, the enhancement of tyrosine hydroxylase in naïve dopaminergic cells and the protective effects in a cellular model of Parkinson's disease suggest that full-length Nurr1 fusion protein may contribute to the development of a novel concept of protein-based therapy.
|
30121937 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease.
|
31220543 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In contrast, moderate DA or TH loss in the substantia nigra (SN), as occurs in aging, is of similar magnitude (~ 40%) to nigral TH loss at bradykinesia onset in Parkinson's disease.
|
30056575 |
2019 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This dysregulation in protein networks of our novel DJ-1-deficient zebrafish model occurs in the early adult stage preceding a Parkinson's disease-related phenotype and the reduction of tyrosine hydroxylase level.
|
31218647 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
(3) CES significantly upregulated the expression of CHAT, nNOS and TH protein in colon of PD rats.
|
31220524 |
2019 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These changes in TH expression and phosphorylation may have predictive validity to estimate risk of PD progression before motor impairment is evident.
|
29331395 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Levels of the dopaminergic neuron marker tyrosine hydroxylase in the striatum and numbers of dopaminergic neurons in the substantia nigra were reduced in PD mice with gut inflammation.
|
31079293 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease.
|
30187283 |
2019 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moxibustion can effectively reduce the death of SN neurons, decrease the occurrence of ferroptosis, and increase the TH activity to protect the neurons in rats with PD.
|
31467572 |
2019 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The results revealed the additive effect of the combined treatment with rapamycin and trehalose on dopaminergic deficits (according to the levels of TH expression in the nigrostriatal system) but not on the behavioral performance in the mouse PD model.
|
30582934 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, after being grafted into the brain caudate putamen of monkeys with MPTP-induced PD, RPE cells became tyrosine hydroxylase-positive cells, and recipient PD monkeys showed significant improvement of clinical conditions.
|
30922214 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease.
|
31704726 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Several strategies have been developed to generate iPSC-derived tyrosine hydroxylase (TH)-positive dopaminergic neurons (DAn), the clinically relevant cell type in PD; however, they often result in mixed neuronal cultures containing only a small proportion of TH-positive DAn.
|
31048719 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the PD model, SKF-38393 administration (3 and 10 mg/kg per day, s.c.) for 8 weeks significantly increased the number of tyrosine hydroxylase-immunopositive neuronal cells in nigrostriatal regions.
|
30930179 |
2019 |